FDA decision: Saroglitazar by Zydus Therapeutics (this year)
As of Fri, 20 Nov 2026 11:52:43 UTC, Kalshi traders price Yes (77.0%). The market has $2K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 77.0% | 77.0¢ | 23.0¢ |
Market details
- Venue: Kalshi
- Volume: $2K
- Liquidity: $2K
- Closes:
Resolution rules
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Sources
Related markets
- Who will be the next CEO of NVIDIA?
- S&P close price end of 2026?
- Nasdaq-100 close price end of 2026?
- Which brands will advertise during the World Soccer Cup Final
- Will GameStop acquire eBay this year?
- When will Apple release the iPhone 18?
More markets like this
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)
- FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)
- FDA decision: Oveporexton by Takeda (this year)
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Fed decision in December?
- Fed decisions (Oct-Jan)
- Fed decisions (Sep–Dec)
- Fed decisions December 2026 to March 2027?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.